BBH - VanEck Vectors Biotech ETF
| Previous Close | 140.49 |
| Open | 140.70 |
| Bid | 137.58 x 1300 |
| Ask | 141.51 x 800 |
| Day's Range | 140.07 - 140.70 |
| 52 Week Range | 113.89 - 143.02 |
| Volume | 22,085 |
| Avg. Volume | 14,595 |
| Net Assets | 362.31M |
| NAV | 140.53 |
| PE Ratio (TTM) | N/A |
| Yield | 0.34% |
| YTD Daily Total Return | 0.71% |
| Beta (5Y Monthly) | 1.28 |
| Expense Ratio (net) | 0.35% |
| Inception Date | 2011-12-20 |
- Zacks
Top ETF Areas for 2020
As ETF investing constantly climbs the popularity charts, we highlight a few good ETF areas that investors can bank on for 2020.
- Zacks
Deal or No Deal: Healthcare ETFs to Make a Sweep in 2020
While all eyes are on the fate of the phase one trade deal between the United States and China, Healthcare sector can forget tension and soar higher in 2020 even if there is no deal.
- Zacks
Is Trade Scaring You? ETF Strategies for 2019 Holiday Season
It is less likely that Santa alone will drive Wall Street this season as trade tensions persist. Overall, these ETF investing trends should stay strong.
- Zacks
Not Santa, Trade Will Rule This December: ETFs to Your Rescue
Despite the age-old trend of a Santa rally, 2018 was a massive downer. Since 2019 is giving the same cues, investors can seek refuge in these safer ETFs.
- Zacks
A Guide to Biotech ETF Investing
Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to work in favor of the biotech market.
- Zacks
Why Biotech ETFs Surged in Monday's Trading Session
Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to drive the biotech market.
- Business Wire
VanEck Announces Preliminary Yearend Distribution Estimates for VanEck Vectors ETFs
VanEck announced today preliminary yearend distribution estimates for its VanEck Vectors® exchange-traded funds.
- ETF Database
Best & Worst Monthly Performers: November 21 Edition
Here is a look at the 25 best and 25 worst ETFs from the past trading month. Traders can use this list to find prospective candidates that have deviated too far from their longer-term trends, thereby serving as potential starting points for those looking to take on either short or long positions. Likewise, traders can also use this list to spot potential trend reversal opportunities that may offer a generous risk/reward. As always, investors of all experience levels are advised to use stop-loss orders and practice disciplined profit-taking techniques. To get access to all ETFdb.com premium content, sign up for a free 14-day trial to ETFdb.com Pro.
- Zacks
Biotech ETF (BBH) Hits New 52-Week High
This biotech ETF hits a new 52-week high. Are more gains in store for this ETF?
- Zacks
Risk-On Sentiments Are Back: ETFs to Play
The global market has been rallying hard since October. Investors can thus bet on these high-flying ETFs.
- Zacks
Biotech ETFs in Focus on Impressive Q3 Earnings Results
Let's take a look at some ETFs with wide exposure to a few biotechnological companies which released solid Q3 earnings results recently.
- Zacks
Value Biotech ETFs & Stocks to Buy Now
Biotech valuation looks attractive amid a volley of good news. Investors can tap these stocks and ETFs.
- Investopedia
Adding Biotech ETFs to Your Portfolio
Biotech ETFs are among the most popular investment vehicles. Here are some reasons for why they're worth considering.
- Zacks
Top-Performing Biotech ETFs YTD
Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to boost the biotech stocks. Accordingly, we take a look at biotech ETFs gaining more than 10% year to date.
- Zacks
Amgen to Buy Celgene's Otezla: 5 ETF Drugs
Amgen agreed to buy psoriasis and psoriatic arthritis drug Otezla from Celgene for $13.4 billion in cash.
- Zacks
Biotech ETFs in Focus on Impressive Q2 Earnings Results
Let's take a look at some ETFs with wide exposure to a few biotechnological companies which released solid Q2 earnings results recently.
- Zacks
AbbVie to Buy Allergan: Prescribed ETFs
AbbVie has agreed to buy Botox-maker Allergan for $63 billion in a cash-and-stock deal. The news has put the spotlight on a number of healthcare ETFs.
- InvestorPlace
3 Large-Cap Biotech Stocks to Buy for Massive Gains
Do you want to find the next Apple (NASDAQ:AAPL) or Amazon (NASDAQ:AMZN)? My advice is that you should set your sights lower, not higher and put some cash to work in three down, but not out heavyweight biotech stocks for the next big thing in investing. Let me explain.It has been a good week so far for the broader markets. The Nasdaq Composite, S&P 500 and Dow Jones Industrial Average have broken out of short bases barely discernible on the weekly chart and back within spitting distance of their respective all-time-highs following May's abrupt correction. It has been a nice period for biotech stocks as well.The Vaneck Vectors Biotech ETF (NYSEARCA:BBH) is up nearly 3.50% through Tuesday's close compared to gains of roughly 1% to 2% for the broader averages. But as any investor with a passing interest in the markets knows, the outperformance in biotech stocks has been anything but a recurring theme these past couple years.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 7 Hot Stocks to Buy for a Seemingly Sleepy Summer The good news is markets are cyclical. Even legendary investments such as AMZN or the sacrosanct AAPL stock have been known to correct for periods lasting not weeks, but months and even years. With that in mind, it's time to consider adding these three large-cap biotech stocks into your portfolio. Amgen (AMGN) Click to EnlargeAmgen (NASDAQ:AMGN) is a biotech heavyweight that also happens to be the sector's largest capitalization outfit with a valuation of about $110 billion.Following a recent sales and earnings beat, this reasonably-priced biotech giant, which pays investors nearly 3.5% in quarterly dividends, has now put together a bottom on the monthly price chart.Specifically, AMGN stock has formed a confirmed pivot low, which reaffirms its longstanding uptrend after a correction of several months. And with plenty of lateral, angular and Fibonacci price supports, as well as an oversold crossover signal to confirm the bottom, this biotech stock is a buy today.The TradeBuy AMGN stock at current prices. Set a stop-loss beneath support below $160, but expect shares to hit new highs in 2019's second half. Gilead Sciences (GILD) Click to EnlargeIt has been a rough few years for Gilead Sciences (NASDAQ:GILD), one the sector's largest names, but things are looking up for GILD stock lately.A recent earnings report that reiterated the company's full-year guidance and offered a modest year-over-year uptick in sales and profits looks promising for Gilead shares, which have been absolutely pummeled over the last four years.Technically, shares are trading slightly above multiple inside candlesticks following a double bottom pattern of about one and a half years. With the formation finding support off the 50% retracement level and a supportive-looking stochastics set-up signaling better months and years ahead, GILD stock looks good to buy right now. * 10 'Buy-and-Hold' Stocks to Own Forever The TradeBuy GILD stock at current levels with an initial stop-loss below $59. On the upside, $85 - $90 looks like a good area for profit-taking while allowing this down-and-out value stock some room to run. Biogen (BIIB) Click to EnlargeMuch like GILD stock, shares of sector heavyweight Biogen (NASDAQ:BIIB) have been under extreme technical duress the past few years.Most recently, the pain in BIIB stock came after the company's announcement that it was axing a drug to treat Alzheimer's following poor results. The suffering came despite the fact that BIIB posted stronger-than-forecast results in late April.On the price chart, this biotech stock's technical beating since 2015 has resulted in a possible four-year long double-bottom pattern that's finding support in-between the 50% and 62% retracement levels. Coupled with an oversold stochastics that is a hair's breadth away from signaling a bullish crossover, confirmation of the pivot low looks imminent.The TradeBuy BIIB stock above May's candle high of $238.17 to confirm the pattern bottom. I'd suggest an initial stop beneath $214 and to take partial profits in-between $300 - $310.Disclosure: Investment accounts under Christopher Tyler's management currently do not own positions in any of the securities mentioned in this article. The information offered is based upon Christopher Tyler's observations and strictly intended for educational purposes only; the use of which is the responsibility of the individual. For additional market insights and related musings, follow Chris on Twitter @Options_CAT and StockTwits. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 7 Value Stocks to Buy for the Second Half * 7 Hot Stocks to Buy for a Seemingly Sleepy Summer * 6 Chip Stocks Staring At Big Headwinds in 2019 Compare Brokers The post 3 Large-Cap Biotech Stocks to Buy for Massive Gains appeared first on InvestorPlace.
- ETF Trends
Biotech ETFs Could Use Some Mergers & Acquisitions
The VanEck Vectors Biotech ETF (BBH) is up nearly 8% year-to-date, but some industry observers are speculating that for large-cap biotechnology stocks to rally again, some more mergers and acquisitions activity will be required. BBH holds 25 stocks and tracks the MVIS US Listed Biotech 25 Index, “which is intended to track the overall performance of companies involved in the development and production, marketing and sales of drugs based on genetic analysis and diagnostic equipment,” according to VanEck. Some well-known biotechnology companies are trailing the broader market this year as the healthcare sector itself is disappointing investors.
- Zacks
Biotech ETFs in Focus on String of Q1 Earnings Beats
Let's take a sneak peek at some ETFs having high exposure to some impactful biotechnological companies on the release of Q1 earnings results.
- Zacks
Will Biotech ETFs Continue to Rally in Q1 Earnings?
Here we study the possible impact of some major Q1 earnings releases on certain biotech ETFs .
- Zacks
Health Day Checkup of Medical ETFs: 5 Top Picks
M&A activity, approval of novel drugs and earnings growth in Q1 put healthcare ETFs in a decent spot.
- Zacks
Top-Ranked ETF Winners in Dow's Longest Rally in 24 Years
While there are winners in many corners of the space, some ETFs have crushed the Dow Jones by wide margins in three months.
- Zacks
Despite M&A Spree, Biotech ETFs Slide on Mixed Earnings
Biotech stocks came up with mixed earnings and weighed on the related ETFs in the key reporting season.
- Zacks
What's Behind the Biotech ETF Rally to Start 2019?
Biotech ETFs have been riding on the wave of mergers and acquisitions as well as drug approvals.
